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Abstract
Background: The emergence of an HIV-1 epidemic in China was first recognized in Dehong, western Yunnan. Due
to its geographic location, Dehong contributed greatly in bridging HIV-1 epidemics in Southeast Asia and China
through drug trafficking and injection drug use; and also extensively to the HIV genetic diversity in Yunnan and
China. We attempt to monitor HIV-1 in this area by studying the HIV-1 genetic distribution and transmitted drug
resistance (TDR) in various at-risk populations.
Methods: Blood samples from a total of 320 newly HIV-1 diagnosed individuals, who were antiretroviral therapy
(ART)-naive, were collected from January 2009 to December 2010 in 2 counties in Dehong. HIV-1 subtypes and pol
gene drug resistance (DR) mutations were genotyped.
Results: Among 299 pol sequences successfully genotyped (93.4%), subtype C accounted for 43.1% (n=129), unique
recombinant forms (URFs) for 18.4% (n=55), CRF01_AE for 17.7% (n=54), B for 10.7% (n=32), CRF08_BC for 8.4%
(n=25) and CRF07_BC for 1.7% (n=5). Subtype distribution in patients infected by different transmission routes
varied. In contract to the previous finding of CRF01_AE predominance in 2002-2006, subtype C predominated in
both injecting drug users (IDUs) and heterosexually transmitted populations in this study. Furthermore, we found a
high level of BC, CRF01_AE/C and CRF01_AE/B/C recombinants suggesting the presence of active viral
recombination in the area. TDR associated mutations were identified in 4.3% (n=13) individuals. A total of 1.3% of
DR were related to protease inhibitors (PIs), including I85IV, M46I and L90M; 0.3% to nucleoside reverse transcriptase
inhibitors (NRTIs), including M184I; and 2.7% to non-nucleoside reverse transcriptase inhibitors (NNRTIs), including
K103N/S, Y181C, K101E and G190A.
Conclusion: Our work revealed diverse HIV-1 subtype distributions and intersubtype recombinations. We also
identified a low but significant TDR mutation rate among ART-naive patients. These findings enhance our
understanding of HIV-1 evolution and are valuable for the development and implementation of a comprehensive
public health approach to HIV-1 DR prevention and treatment in the region.
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Background
Dehong prefecture is located in western Yunnan borde-
ring northern Myanmar. It is in a key position along the
drug trafficking routes from Southeast Asia’s opium-
producing and high HIV prevalent “Golden Triangle”
region into China [1]. The first HIV epidemic in China
with the identification of 146 infected IDUs was reported
in Dehong in 1989 [2]. To date, Dehong remains one of
the most HIV-affected areas in China [3,4].
Subtype B and subtype B' (the B subtype originally
found in Thailand) were the HIV-1 strains first found
among infected Dehong IDUs [5-7]. The proportion of
subtype B' among the subtype B category increased from
20% in 1990 to 90% in 1996 [5-7]. Subtype C was identi-
fied in IDUs from India in the early 1990s [8] and cocir-
culated with B' in the IDUs in western Yunnan in the
first half of the 1990s resulting in many recombinant
viruses [9-12]. Another CRF01_AE subtype was also
found in this region in 1994 [13] and, with increased
sexual contacts, became the predominant strain in 2000
[9,10]. Other viral strains, CRF07_BC and CRF08_BC,
were also found in Dehong in 2002 [9,10,12].
To combat the growing HIV infection, China initiated
a national free ART program with standardized treat-
ment options and management protocols in 2003 and by
the end of 2010, the total number of ART patients
exceeded 100,000. Although the widespread use of
highly active ART successfully decreases HIV/AIDS-
related mortality and morbidity [14,15], suboptimal ART
adherence may accelerate the emergence of drug resist-
ant viruses [16] and compromise ART efficacy in treated
individuals and transmission recipients. It was reported
that suboptimal ART management in central China
resulted in the rise of DR rate from 13.9%, 45.4% to
62.7% in individuals who were ART-naive and 3- and 6-
months post-ART, respectively [17]. By the end of 2010,
of the 19,512 ART patients in Yunnan, 20% resided in
Dehong. It is important to conduct HIV DR surveys to
estimate the TDR rate among ART-naive populations
with different transmission routes to provide baseline
information for the formulation of effective ART regi-
mens to delay the emergence of DR and to develop a
rational public health strategy to control the HIV
epidemic.
Methods
Study area, population and sampling
Blood samples were collected from 320 individuals newly
diagnosed with HIV-1 infection in Longchuang and Luxi
counties of Dehong prefecture between January 2009 and
December 2010. HIV-1 infection was confirmed by
Western Blot assay (HIV BLOT 2.2, MP Diagnostics,
Singapore). All study participants were ART-naive and
provided informed consent. This study was approved by
the institutional review board of Yunnan Center for Di-
sease Control and Prevention.
Amplification and sequencing of HIV-1 pol
Viral RNA was extracted from 200 μl plasma using an
automated extractor (MagNA Pure LC system, Roche,
Branchburg, NJ) according to the manufacturer’s
instructions. For the amplification of the pol regions, an
in-house nested reverse transcription PCR method was
used. The target sequence was amplified with One Step
Reverse Transcription PCR reagents procured from
Takara (Dalian, China) using primers MAW26 (50-TTG
GAAATGTGGAAAGGAAGGAC-30) and RT21 (50-CT
GTATTTCTG CTATTAAGTCTTTTGATGGG-30) in a
25 μl reaction for 30 cycles. Cycling conditions were 50°C
for 30 min, 94°C for 5 min, 94°C for 30 s,55°C for 30 s,
72°C for 2.5 min, followed with an extension at 72°C for
10 min. The nested PCR was performed using Taq PCR
master mix (Tiangen, Beijing, China), using primers PRO-
1 (50-CAGAGCCAACAGCCCCACCA-30) and RT20 (50-
CTGCCAGTTCTAGCTCTGCTTC-30) in a 50 μl reaction
for 30 cycles and the cycling conditions were 94°C for 5
min, 94°C for 30 s, 63°C for 30 s, 72°C 2.5 min, followed
with an extension at 72°C for 10 min. The resulting PCR
product of 1191 bp in length contained a full length pro-
tease (PR) gene of 99 amino acid codons and the first 298-
codon segment of the reverse transcriptase (RT) gene. PCR
products were visualized by 1% agarose gel electrophoresis.
Successfully amplified samples were sequenced by Biomed
Co. (Beijing, China) on an ABI 3730xl automated DNA
analyzer (Applied Biosystems, Foster City, CA) with pri-
mers: PROS3 (50-GCCAACAGCCCCACCA-30), RTAS
(50-CTCAGATTGGTTGCAC-30), RTB (50-CCTAGTA
TAAACAATGAGACAC-30), PROC1S (50-GCTGGGTGT
GGTATTCC-30) and RT20S3 (50-GTTCTAGCTCTGCT
TC-30). Each step was carried out with appropriate negative
controls to detect PCR-related contamination during the
experiments.
Sequence analysis
The sequence contig assembly was performed using
analysis software, Sequencher 4.9 (Gene Codes Corpo-
ration, Ann Arbor, MI). The ClustalW Multiple alignment
and manual editing were performed using BioEdit
Sequence Alignment Editor (Ibis Biosciences, Carlsbad,
CA). Edited sequences were evaluated for DR mutations
using both the Surveillance Drug Resistance Mutations
(SDRM) list recommended by the World Health
Organization [18], and the Stanford University Algorithm
(http://hivdb.stanford.edu). The HIV-1 subtypes of pol
sequences were identified by the REGA HIV subtyping
tool (http://www.bioafrica.net/subtypetool/html/) [19]. To
demonstrate possible intersubtype mosaicism, candidate
sequences were analyzed using the Recombination
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Identification Program (RIP; version 3.5.1) available at the
HIV sequence database site (http://hiv-web.lanl.gov). Boot-
scanning analysis was performed with default parameters of
window: 200bp, step: 20bp, gapsrip: on, reps: 100, Kinura
(2-parameter), T/t: 2.0. Similarity plot analysis (SimPlot ver-
sion 3.5.1; S. Ray, Johns Hopkins University, Baltimore,
MD; http://sray.med.som.jhmi.edu/RaySoft/SimPlot/) was
performed using reference A1, B, C, CRF07_BC, CRF08_BC
and CRF01_AE strains. All sequences obtained in this
study were submitted to GenBank with accession num-
bers from JQ658474 to JQ658772.
Statistical analysis
Statistical analysis was conducted using the SPSS 17.0
package (SPSS Inc. Chicago, IL). Categorical variables
were compared using chi-square analysis. When the the-
oretical frequency was less than 5, Fisher exact test was
used. All tests were two-tailed and a p-value <0.05 was
considered significant.
Results
Demographic characteristics of patients
A total of 320 individuals diagnosed with HIV-1 infec-
tion between 2009 and 2010 were recruited from two
counties in Dehong prefecture. Two hundred ninety
nine sequences (93.4%) of HIV-1 pol region were suc-
cessfully amplified and sequenced. The demographics of
these individuals are shown in Table 1. The ratio of
males to females was 1:0.78 and the mean age was 32.5
years (range: 2-74 years). Heterosexual transmission
Table 1 Demographic characteristics and HIV DR of study individuals
Total N (%) No. of resistant mutations Resistance rate (%)
Total 299 (100) 13 4.5
Gender
Male 168 (56.2) 7 4.3
Female 131 (43.8) 6 4.8
Age
≤25 75 (25.1) 3 4.2
26-35 130 (43.5) 6 4.8
36-45 58 (19.4) 4 7.4
>45 36 (12.0) 0 0
Transmission routes
Heterosexual 227 (75.9) 8 3.7
Intravenous drug injection 52 (17.4) 5 10.6
Homosexual 2 (0.7) 0 0
Mother to child 4 (1.3) 0 0
Unknown 14 (4.7) 0 0
Ethnicity
Han 122 (40.8) 3 2.5
Jingpo 98 (32.8) 7 7.7
Dai 64 (21.4) 2 3.2
Others 15 (5.0) 1 7.1
CD4+ Count (cells/μl)
≤200 21 (7.0) 1 5.0
201-350 64 (21.4) 3 4.9
351-500 88 (29.4) 4 4.8
≥501 126 (42.1) 5 4.1
HIV-1 Subtype
C 129 (43.1) 7 5.7
URFs 55 (18.4) 2 3.8
CRF01_AE 53 (17.7) 1 1.9
B 32 (10.7) 2 6.7
CRF08_BC 25 (8.4) 1 4.2
CRF07_BC 5 (1.7) 0 0.0
Abbriviations: URFs, unique recombinant forms; CRFs, circulating recombinant forms.
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constituted the most frequent transmission route (75.9%,
n=227), followed by intravenous drug injection (17.4%,
n=52), mother-to-infant transmission (1.3%, n=4) and
homosexual transmission (0.7%, n=2). The transmission
route of the remaining 4.7% (n=14) individuals was un-
known. The ethnicities of the studied individuals were
Han (40.8%, n=122), Jingpo (32.8%, n=98), Dai (21.4%,
n=64), Achang (2.3%, n=7), Deang (1.3%, n=4), Bai
(1.0%, n=3), and Dongxiang (0.3%, n=1). There were also
10 Burmese individuals. In addition, 28.4% (n=85) of the
individuals had CD4 cell count lower than 350 cells/μl
and were ART-eligible.
HIV-1 subtypes distribution
HIV-1 pol gene sequences (1191 bp) were subjected to
subtype determination [20]. As revealed in Table 1, 6
basic subtypes were identified. HIV-1 C subtype was
found to be the most common subtype (43.1%, n=129),
followed by URFs (18.4%, n=55), CRF01_AE (17.7%,
n=53), B (10.7%, n=32), CRF08_BC (8.4%, n=25) and
CRF07_BC (1.7%, n=5). Bootscanning analysis revealed
the presence of 55 (18.4%) URFs including 48 BC
recombinants (16.1%, Figure 1C and D), 6 CRF_01AE/C
(2.0%, Figure 1E-I) and 1 CRF_01AE/B/C (0.3%,
Figure 1J). The prevalence of URF (18.4%) was similar to
that of CRF01_AE (17.7%) and revealed frequent recom-
bination among the main strains (subtype C, CRF01_AE
and subtype B). Most URFs (76.4%, 42/55) were found in
individuals infected through heterosexual contact
(Table 2). Seven of the HIV sequences derived from the
10 Burmese individuals were subtype C and the other 3
were URF_BC.
The presence of subtypes/CRFs varied with different
transmission routes. As shown in Table 2, all 6 geno-
types were found in the heterosexually transmitted
population. Five genotypes, with the exception of
CRF07_BC, were detected in IDUs. One subtype C, 1
URF and 2 CRF01_AE strains were detected in the 4
young children infected through mother-to-child trans-
mission; 1 CRF01_AE strain and 1 CRF07_BC strain in 2
persons who were men having sex with men. The pro-
portions of HIV-1 genotypes in heterosexually transmit-
ted population and IDUs showed a statistical difference
(χ2=13.801, p=0.013) suggesting that different subtype
distribution patterns were associated with different
infection routes. The proportion of subtype C among
IDUs (61.5%) was significantly higher than that among the
heterosexually transmitted population (39.2%, χ2=8.591,
p=0.005). Likewise, the proportion of CRF01_AE in
the heterosexually transmitted population (18.9%) was
Figure 1 Bootscanning analysis of new viral recombination in HIV-1 pol gene region. (A) the reference sequence of CRF07_BC; (B) the
reference sequence of CRF08_BC; (C) representative BC recombinant YN09S0012; (D) representative BC recombinant, YN09S0054; (E to I),
representative CRF_01AE/C recombinant, E: YN09S0046, F: YN10S0018, G: YN10S0087, H: YN10S0042 and I: YN10S0038; and (J) representative
CRF_01AE/B/C recombinant, YN09S0068. The conditions used for this analysis were following: Window: 200 bp, step: 20 bp, gapsrip: on, reps: 100,
Kinura (2-parameter), T/t: 2.0.
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significantly higher than that among IDUs (5.8%, χ2=5.332,
p=0.022). The proportions of URFs, subtype B and
CRF08_BC showed no statistical difference in these two
populations.
Genotypic analysis of DR
To detect TDR-associated mutations, the pol sequences
were screened against those within the Stanford HIV
Drug Resistance Database (http://hivdb.stanford.edu).
DR-related mutations were identified in 13 of the 299
viral sequences (4.3%). With the exception of one indi-
vidual who had 2 NNRTI mutations, the other 12 indi-
vidual harbored virus with 1 DR mutation each. The
demographic characteristics of these 13 ART-naive indi-
viduals are shown in Table 3. The mean age was 32.5
years. The mean CD4 cell count was 467 cells/μl and 4
individuals were ART eligible. No statistical difference
was observed in distribution of DR strains by gender,
age, infection route, ethnicity, CD4 cell count or HIV-1
subtype. Eight were infected through heterosexual trans-
mission and the other 5 through intravenous drug injec-
tion. One individual (YN10S0137) was Burmese.
The proportion of sequences with TDR mutation asso-
ciated with NRTIs, NNRTIs, and PIs was 0.3% (n=1),
2.7% (n=8), and 1.3% (n=4), respectively. Sequences con-
taining mutations associated with 2 or 3 classes of anti-
retroviral drugs were not found. The PI-related DR
included: I85V (0.67%, n=2), M46I (0.33%, n=1) and
L90M (0.33%, n= 1). Although I85V is a nonpoly-
morphic PI-selected mutation, it does not result in
resistance to PI. Only 1 NRTI-related DR mutation,
M184I (0.33%, n=1), was detected. Among NNRTI-
related DR mutations, K103N and Y181C were found in
3 samples (1.0%). K103N causes high-level resistance to
nevirapine (NVP) and efavirenz (EFV). Y181C causes
high-level resistance to NVP and intermediate resistance
to EFV, etravirine (ETR) and rilpivirine (RPV). Impor-
tantly, Y181C forms the foundation for high-level ETR
and RPV resistance as an addition of some single muta-
tions and many double mutations causes high-level re-
sistance to these drugs. Three individuals were found to
have one other NNRTI-related mutation (K103NS,
K101E and G190A) each (0.33%).
Based on the interpretation of the Stanford HIV Drug
Resistance Database, the 13 drug resistant viruses showed
different levels of resistance to 11 antiretroviral drugs
(Figure 2). Although lopinavir (LPV) and indinavir (IDV)
were the main PIs used in Dehong, low-level resistance to
Table 2 The constitution of HIV-1 subtypes in different transmission routes
Transmission route Subjects C URFs CRF01_AE B CRF08_BC CRF07_BC χ2 P*
Heterosexual 227 (100%) 89 (39.2%) 42 (18.5%) 43 (18.9%) 25 (11.0%) 24 (10.6%) 4 (1.8%) 13.801 0.013
Intravenous drug injection 52 (100%) 32 (61.5%) 9 (17.3%) 3 (5.8%) 7 (13.5%) 1 (1.9%) 0 (0%)
Homosexual 2 (100%) 0 (0%) 0 (0%) 1 (50.0%) 0 (0%) 0 (0%) 1 (50.0%)
Mother to child 4 (100%) 1 (25.0%) 1 (25.0%) 2 (50.0%) 0 (0%) 0 (0%) 0 (0%)
Unknown 14 (100%) 7 (50.0%) 3 (21.4%) 4 (28.6%) 0 (0%) 0 (0%) 0 (0%)
*: Compared the proportions of subtypes between groups of heterosexual contact and intravenous drug injection.
Table 3 Demographic characteristics of 13 individuals infected by viruses containing DR mutations
Sequence
ID






YN09S0004 Male 37 Intravenous drug injection Jingpo 383 -* K103N - B
YN09S0012 Male 55 Heterosexual Han 506 - - M46I BC
YN09S0021 Female 42 Heterosexual Jingpo 149 - K103N - CRF01_AE
YN09S0027 Female 29 Heterosexual Achang 225 - K101E - C
YN09S0054 Female 38 Heterosexual Jingpo 280 - K103N, Y181C - BC
YN09S0072 Female 31 Heterosexual Jingpo 422 - K103NS - B
YN09S0092 Female 19 Intravenous drug injection Han 335 - Y181C - C
YN09S0114 Male 24 Heterosexual Jingpo 882 - G190A - C
YN09S0129 Male 25 Heterosexual Jingpo 608 - - L90M CRF08_BC
YN10S0097 Male 34 Intravenous drug injection Han 639 - - I85V C
YN10S0132 Male 33 Intravenous drug injection Dai 475 - Y181C - C
YN10S0137 Female 22 Heterosexual Burmese 473 M184I - - C
YN10S0138 Male 33 Intravenous drug injection Jingpo 687 - - I85V C
*: not detected.
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atazanavir (ATV), fosamprenavir (FPV), IDV, nelfinavir
(NFV) and saquinavir (SQV) was detected. Among RTIs,
intermediate and high-level resistance to 4 NNRTIs
(EFV, ETR, NVP and RPV) and high-level resistance to 2
NRTIs (lamivudine (3TC) and emtricitabine (FTC)) were
detected, of which 2 NNRTIs (ETR and RPV) and 1 NRTI
(FTC) were not used in local patients. The reason for their
presence might be due to cross-resistance, for example
3TC induced M184I/V but also rendered resistance to
FTC. Further, cross-resistance was a common phenomenon
among NNRTIs. The existence of cross-resistance could
increase the complexity and the length of ART.
Discussion
Yunnan has been described as a “key HIV epicenter in
China” [21]. By the end of 2010, the cumulative number
of HIV/AIDS cases reported in Yunnan was 83,925 and
accounted for 21% of total HIV/AIDS cases in China.
With the scale up of ART in Yunnan, the emergence of
HIV DR is anticipated. The surveillance of emergence
and transmission of drug resistant HIV-1 strains is one
of the priorities for HIV/AIDS prevention and control in
Yunnan. In particular, surveying the characteristics and
trends of TDR among newly reported cases of HIV
infection could provide valuable information for evalua-
ting the efficacy of ART, public health planning [22], and
the selection of pre- and post-exposure prophylaxis.
By using a standard genotyping protocol, we carried
out a survey of TDR in 299 newly HIV-1 diagnosed and
ART-naive individuals residing in Dehong. Our study
revealed a low TDR rate of 4.3%. An earlier study con-
ducted in 2006 of 64 newly infected HIV-1 patients
whose infections were classified to be recent by BED
incidence assay yielded a rate of 6.3% [23]. No statistical
difference between the rates of these 2 studies (p>0.05)
was found. This indicates that the prevalence of drug
resistant HIV-1 strains remained relatively constant over
the 5 years between 2006 and 2010, and that the man-
agement of treated individuals with standardized ART
protocol appeared to be efficient in western Yunnan. In
this study, we also found one DR strain among 10
Burmese individuals. Further vigilance needs to be
placed to monitor the importation of DR strains from
neighboring countries.
The first-line regimens of the Chinese national free
ART program include 2 NRTIs and 1 NNRTI. The ART
drugs presently used in Dehong include 6 NRTIs (abaca-
vir (ABC), zidovudine (AZT), stavudine (D4T), didano-
sine (DDI), tenofovir (TDF) and 3TC, two NNRTIs (EFV
and NVP), and two PIs (LPV and IDV). A total of 69.2%
of drug resistant strains found in this study were RTI-
associated. These DR mutations (M184I, K103N/S,
Y181C and K101E) could derive from ART-treated
patients in Yunnan [24]. Further, intermediate and high-
level resistance to four NNRTIs was detected with
increased frequency. The increased rates of RTI relevant
resistance strains could increase the failure of the first-
line antiretroviral regimens. The use of PIs is limited
and PI-related DR mutations were not previously found
among the treated population in 2008 in Yunnan [24].
Five PI-related DR strains were detected in this study. A
possible explanation for the presence of DR to PIs differ-
ent from the ones used in Dehong (LPV and IDV) is that
the individuals were administering self-procured PIs
from overseas or the observed mutations were intro-
duced by foreigners.
Figure 2 The presence of DR from 13 individuals with DR strains. PI: protease inhibitor; NRTI: nucleoside reverse transcriptase inhibitor;
NNRTI: non-nucleoside reverse transcriptase inhibitor; ATV: atazanavir; DRV: darunavir; FPV: fosamprenavir; IDV: indinavir; LPV: lopinavir; NFV:
nelfinavir; SQV: saquinavir; TPV: tipranavir/r; 3TC: lamivudine;ABC: abacavir;AZT: zidovudine;D4T: stavudine;DDI: didanosine;FTC: emtricitabine;TDF:
tenofovir;EFV:efavirenz; ETR: etravirine;NVP:nevirapine;RPV:rilpivirine.
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In this study, we found that most subtypes/CRFs were
present in both the heterosexually transmitted population
and IDUs. This finding suggests that various HIV-1
subtypes/CRFs were disseminating between different high-
risk populations via complicated transmission routes and/
or introduced by bridging populations such as female sex
workers. Extensive BC recombinants were previously
detected among IDUs in Dehong [9,10,12]. In this work,
we found increased intersubtype recombinants in IDUs
and the heterosexually transmitted population. In addition
to BC recombinants, CRF01_AE and subtype C or BC
recombinants were also identified for the first time in this
area. Recently, extensive and complex HIV-1 recombi-
nation events between B', C and CRF01_AE were found in
the neighboring northern Myanmar area [25]. Thus, the
China-Myanmar border area appears to be a hot spot of
active viral recombinant events. In order to effectively
control the HIV epidemic in this area, comprehensive
strategies including risk behavior interventions, enhanced
HIV testing and proper use of ART should be emphasized.
As a linkage between the HIV-1 epidemics in South-
east Asia and China, Dehong converges many HIV-1
strains circulating in this area [8,13,26,27]. Dehong was
also affected by the epidemic in other parts of China.
For example, CRF07_BC and CRF08_BC were first
detected from IDUs in Xinjiang province and Guangxi
province in 1997, respectively [28,29]. However, it is
believed that these two CRFs were initially formed in
Yunnan Province [30] and spread through two different
overland heroin trafficking routes. CRF07_BC spread
northwestward to Xinjiang, and CRF08_BC eastward to
Guangxi. As reported previously, these 2 CRFs were not
identified in western Yunnan until 2002 [9,10,12] but
were predominant in eastern Yunnan prior to 2002,
including Honghe and Wenshan prefectures [12]. Thus,
it is likely that these 2 CRFs might have formed in
eastern Yunnan and spread to western Yunnan. Further-
more, the epidemic could potentially influence neighbo-
ring countries if infected individuals and drug trafficking
are not monitored and managed efficiently.
Conclusions
This study of HIV-1 genetic diversity and TDR-associated
mutations among ART-naive individuals in Dehong,
Yunnan reveals distinct subtype distribution patterns in
the heterosexually transmitted population and IDUs.
While subtype C was the most frequently found virus in
both populations, CRF01_AE was found to circulate more
frequently in the heterosexually transmitted population.
Strikingly, the URF recombinant events continued to rise
with a prevalence second only to subtype C. The overall
prevalence of TDR remained low in newly HIV-1 diag-
nosed and ART-naive individuals. HIV drug resistant
mutations in these individuals represent a great challenge
for the future of the ART program. Our findings could
better guide us in the development of efficacious and
effective management plans and strategies to prevent the
transmission of drug resistant strains of HIV-1.
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